For Immediate Release


Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126

Daiichi Sankyo Announces Reorganization of Research & Development System

Tokyo, Japan (January 10, 2017)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma Private Limited (location: Gurgaon, India; hereafter, DSIN), to increase R&D productivity.


Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.


DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo’s R&D Division.